Результаты поиска - David M. Pariser

Отмена результатов
  1. 1
    Topical 0.5% Ivermectin Lotion for Treatment of Head Lice

    Topical 0.5% Ivermectin Lotion for Treatment of Head Lice по David M. Pariser, Terri L. Meinking, Margie Bell, William G. Ryan

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  2. 2
    The Epidemiology, Etiology, and Pathophysiology of Onychomycosis

    The Epidemiology, Etiology, and Pathophysiology of Onychomycosis по Richard K. Scher, Phoebe Rich, Boni E. Elewski, David M. Pariser

    Опубликовано 2013
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  3. 3
    The electric field near human skin wounds declines with age and provides a noninvasive indicator of wound healing

    The electric field near human skin wounds declines with age and provides a noninvasive indicator of wound healing по Richard Nuccitelli, Pamela Nuccitelli, Changyi Li, Suman Narsing, David M. Pariser, Kaying Lui

    Опубликовано 2011
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  4. 4
    A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis

    A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis по David M. Pariser, Brad Schenkel, Chureen Carter, Kamyar Farahi, T. Michelle Brown, Charles N. Ellis

    Опубликовано 2015
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States

    Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States по Alexa B. Kimball, Jennifer Schenfeld, Neil A. Accortt, Mary S. Anthony, Kenneth J. Rothman, David M. Pariser

    Опубликовано 2015
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    Hematologic Safety of Dapsone Gel, 5%, for Topical Treatment of Acne Vulgaris

    Hematologic Safety of Dapsone Gel, 5%, for Topical Treatment of Acne Vulgaris по Warren W. Piette, Susan C. Taylor, David M. Pariser, Michael Jarratt, Pranav Sheth, David J. Wilson

    Опубликовано 2008
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis

    Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety... по Robert Bissonnette, David M. Pariser, Norman Wasel, Joana Gonçalves, Robert M. Day, Rongdean Chen, Michael Sebastian

    Опубликовано 2016
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up

    Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follo... по Eduardo Tschen, David S.Y. Wong, David M. Pariser, F E DUNLAP, Anna Houlihan, Mary Beth Ferdon

    Опубликовано 2006
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis

    A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patient... по Kim Papp, David M. Pariser, Mary Catlin, G. Wierz, Greg Ball, B. Akinlade, Bernhardt Zeiher, James G. Krueger

    Опубликовано 2015
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis

    Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis по Amy S. Paller, Elaine C. Siegfried, David M. Pariser, Kara Rice, Mona Trivedi, Jan Iles, David H. Collier, Greg Kricorian, Richard Langley

    Опубликовано 2016
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials

    Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials по Linda Stein Gold, Mark Lebwohl, Jeremy Sugarman, David M. Pariser, Tina Lin, Gina Martin, Radhakrishnan Pillai, Robert J. Israel, Tage Ramakrishna

    Опубликовано 2018
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials

    Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials по Dee Anna Glaser, Adelaide A. Hebert, Alexander Nast, William Philip Werschler, Lawrence Green, Richard D. Mamelok, Janice Drew, John Quiring, David M. Pariser

    Опубликовано 2018
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial

    TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial по Seth Forman, David M. Pariser, Yves Poulin, Michael S. Vincent, Steven A. Gilbert, Elizabeth Kieras, Ruolun Qiu, Dahong Yu, Jocelyne Papacharalambous, Christopher Tehlirian, Elena Peeva

    Опубликовано 2020
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  14. 14
    Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

    Etanercept Treatment for Children and Adolescents with Plaque Psoriasis по Amy S. Paller, Elaine C. Siegfried, Richard Langley, Alice B. Gottlieb, David M. Pariser, Ian Landells, Adelaide A. Hebert, Lawrence F. Eichenfield, Vaishali Patel, Kara Creamer, Angelika Jahreis

    Опубликовано 2008
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  15. 15
    Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

    Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies по Mark Boguniewicz, Andrew Alexis, Lisa A. Beck, Julie Block, Lawrence F. Eichenfield, Luz Fonacier, Emma Guttman‐Yassky, Amy S. Paller, David M. Pariser, Jonathan I. Silverberg, Mark Lebwohl

    Опубликовано 2017
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  16. 16
    Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis

    Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis по Eric L. Simpson, Laurent Eckert, Abhijit Gadkari, Usha G. Mallya, Min Yang, Lauren Nelson, T. Michelle Brown, Matt Reaney, Puneet Mahajan, Isabelle Guillemin, Mark Boguniewicz, David M. Pariser

    Опубликовано 2019
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  17. 17
    A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis

    A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis по Mark Lebwohl, Stephen K. Tyring, Tiffani K. Hamilton, Darryl Toth, Scott D. Glazer, Naji Tawfik, Patricia A. Walicke, Wolfgang Dummer, Xiaolin Wang, Marvin R. Garovoy, David M. Pariser

    Опубликовано 2003
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  18. 18
    Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)

    Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT) по David M. Pariser, Eric L. Simpson, Abhijit Gadkari, Thomas Bieber, David J. Margolis, T. Michelle Brown, Lauren Nelson, Puneet Mahajan, Matthew Reaney, Isabelle Guillemin, Usha G. Mallya, Laurent Eckert

    Опубликовано 2019
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  19. 19
    Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial

    Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the op... по Diamant Thaçi, Ronald Vender, Menno A. de Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Haitian Wang, Cynthia Madden, Dirk De Cuyper, Alexa B. Kimball

    Опубликовано 2023
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  20. 20
    OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results

    OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results по Alexa B. Kimball, Kenneth J. Rothman, Gregory Kricorian, David M. Pariser, Paul S. Yamauchi, Alan Menter, Craig Teller, Girish Aras, Neil A. Accortt, Michele Hooper, Kara Rice, Joel M. Gelfand

    Опубликовано 2014
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: